Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine

HONG KONG and HANGZHOU, China, April 30, 2026 /PRNewswire/ -- Hangzhou Diagens Biotech Co., Ltd. (HKEX: 2526, "Diagens"), a pioneer in medical imaging foundation models, today announced its first annual results since its listing. The report marks a pivotal milestone in the company's...